explore -WSS

explore

author：knowledge 2025-08-23 18:39:04 - browse：5661

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Insmed lung disease drug hits target in key Phase 3 trial

WSS

Akili, maker of video game for ADHD, to be acquired for 34 million

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Stigma and the return of syphilis

Medicare to cover more brain scans related to Alzheimer’s drugs

Insmed lung disease drug hits target in key Phase 3 trial

AI used to predict Covid

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

At least 13 dead in Texas as scorching temps continue

Life sciences deals on track to hit lowest point since 2017

The cancer drug shortage isn’t new — and neither are the solutions

STAT Readout: Today's biotech news includes Sana and Amylyx

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Takeaways from AdvaMed, the largest medical devices conference

At least 13 dead in Texas as scorching temps continue

Insmed lung disease drug hits target in key Phase 3 trial

Cancer drug shortages should be causing more outrage

Female surgeons have lower rates of long

hotspot

Humana CEO Bruce Broussard to step down in 2024

Health insurers say they are turning to AI to cut costs, improve care

Takeaways from AdvaMed, the largest medical devices conference

Eight reasons why you should get an updated Covid vaccine

Insmed lung disease drug hits target in key Phase 3 trial

Bernie Sanders bashes nonprofit hospitals over their tax breaks

hotspot

focus

hotspot

entertainment